Since the Company incurred net losses for the three and nine months ended September 30, 2026 and 2025, common stock equivalents were excluded from the calculation of diluted net loss per share for such periods as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share were the same for such periods. The weighted-average number of common shares outstanding used in the basic and diluted net loss per share calculations includes the weighted-average effect of pre-funded warrants to purchase shares of the Company's common stock, as the pre-funded warrants are exercisable at any time for nominal cash consideration. The following potentially dilutive common stock equivalents outstanding at the end of the period were excluded from the computations of weighted-average diluted common shares for the periods indicated as their effects would be anti-dilutive (in thousands):


	Three and Nine Months Ended September 30,
	2026		2025
Stock options outstanding		10,558		11,726
Unvested RSUs		2,884		2,904
Unvested PSUs		184		—
Employee stock purchase plan		68		60
May 2025 Warrants outstanding		268		268
		13,962		14,958

In addition to the common stock equivalents in the table above, the computations of weighted-average diluted common shares for the three and nine months ended September 30, 2026 exclude 122,565 unvested PSUs as of September 30, 2026 for which vesting is contingent upon the future achievement of performance conditions.